Lipid Metabolism Reprogramming and Trastuzumab Resistance in Breast Cancer Cell Lines Overexpressing the ERBB2 Membrane Receptor
暂无分享,去创建一个
K. Cortese | P. Castagnola | M. Gagliani | S. Tavella | M. Ponassi | Erika Iervasi | G. Bellese | A. Profumo | G. Coronel Vargas
[1] S. Swain,et al. Targeting HER2-positive breast cancer: advances and future directions , 2022, Nature Reviews Drug Discovery.
[2] K. Knutson,et al. Resistance to Trastuzumab , 2022, Cancers.
[3] M. Moasser. Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions , 2022, Cancer research.
[4] Min Hwan Kim,et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. , 2022, The New England journal of medicine.
[5] Hongjun Fei,et al. A Novel Autophagy-Related Prognostic Risk Model and a Nomogram for Survival Prediction of Oral Cancer Patients , 2022, BioMed Research International.
[6] A. Brazma,et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences , 2021, Nucleic Acids Res..
[7] Zhixiang Wang,et al. Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma , 2021, Cancers.
[8] Takeshi Yamaguchi,et al. Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy , 2020, Scientific Reports.
[9] P. De,et al. The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies. , 2020, American journal of cancer research.
[10] M. Kurokawa,et al. Lipid metabolic reprogramming as an emerging mechanism of resistance to kinase inhibitors in breast cancer , 2020, Cancer drug resistance.
[11] A. K. Munirajan,et al. Akt in cancer: Mediator and more. , 2019, Seminars in cancer biology.
[12] C. Sotiriou,et al. CD36-Mediated Metabolic Rewiring of Breast Cancer Cells Promotes Resistance to HER2-Targeted Therapies , 2019, Cell reports.
[13] I. Berindan‐Neagoe,et al. A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer , 2019, Cancers.
[14] F. Setién,et al. Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer , 2019, Breast Cancer Research.
[15] K. Cortese,et al. The chromodomain helicase CHD4 regulates ERBB2 signaling pathway and autophagy in ERBB2+ breast cancer cells , 2019, Biology Open.
[16] T. Ignatov,et al. Loss of HER2 after HER2-targeted treatment , 2019, Breast cancer research and treatment.
[17] K. Cortese,et al. Cooperative antitumor activities of carnosic acid and Trastuzumab in ERBB2+ breast cancer cells , 2017, Journal of experimental & clinical cancer research : CR.
[18] Xiaofeng Dai,et al. Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping , 2017, Journal of Cancer.
[19] David J. Odde,et al. Slit-Robo GTPase-Activating Protein 2 as a metastasis suppressor in osteosarcoma , 2016, Scientific Reports.
[20] B. Győrffy,et al. A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer. , 2015, Current cancer drug targets.
[21] S. Kane,et al. t-Darpp Promotes Enhanced EGFR Activation and New Drug Synergies in Her2-Positive Breast Cancer Cells , 2015, PloS one.
[22] Jingwen Zhang,et al. Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistance , 2015, Scientific Reports.
[23] Takeshi Yamaguchi,et al. Comprehensive DNA Methylation and Extensive Mutation Analyses of HER2-Positive Breast Cancer , 2015, Oncology.
[24] G. Damonte,et al. Trastuzumab quantification in serum: a new, rapid, robust ELISA assay based on a mimetic peptide that specifically recognizes trastuzumab , 2014, Analytical and Bioanalytical Chemistry.
[25] Andre T Baron,et al. Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells. , 2009, Cancer research.
[26] S. Ropero,et al. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[27] Ming Tan,et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.
[28] Lyndsay N Harris,et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] G. Hortobagyi,et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[31] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[32] Zhixiang Wang. ErbB Receptors and Cancer. , 2017, Methods in molecular biology.
[33] H. Lane,et al. Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.